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Abstract
Background: Human placental villous cytotrophoblasts exhibit relative externalization of negatively charged
moieties to the outer leaflet of the plasma membrane during the time of syncytialization rendering their reactivity
to positively charged cationic antimicrobial peptides (CAMPs) during the window of implantation and early
placentation. Vaginal administration of a synthetic CAMP, Ala8,13,18-magainin II amide (AMA) inhibited blastocyst
implantation and early placentation in monkeys. Furthermore, the administration of AMA resulted in significant
inhibition of cell differentiation, enhancement in apoptosis and loss of viability in first trimester placental villous
cytotrophoblasts in primary culture. The present study examines the effect of in vitro application of different doses
(0, 1, 10, 100, 1000 ng/ml) of AMA on the secreted cytokine profiles of cytotrophoblasts obtained from placental villi
samples (n = 13) collected during 8–9 weeks of gestation and grown on three-dimensional collagen matrix in vitro.
Methods: A panel of forty-eight (48) cytokines in conditioned medium was analysed using multiplex immunoassays
technique. Further, the steady state transcript levels of four cytokines (CCL4, CCL5, IL1B, IL6), the concentrations of
which were affected by AMA in the isolated cytotrophoblasts, as well as, two cytokines (IL1A and TNF) which were
not affected by AMA were estimated. Input list of cytokines secreted by cytotrophoblasts and showing differential
secretion in response to AMA were used in enrichment analysis for the generation of biological networks.
Results: Placental cytotrophoblasts secreted 27 cytokines, 13 of which are affected by AMA in vitro with
significantly decreased secretion of CCLs-2, 3, 4, 5, CXCLs-1 and 8, FGF2 and MCSF and that of IL1B, IL6 and MIF,
and increased secretion of IL16 and IL-2RA. Of the above cytokines showing differential secretion, only IL-2RA, IL16
and MIF showed significant correspondence in the steady state expression of their respective transcript levels. Post-
hoc Enrichment analysis revealed Toll-like receptor (TLR) mediated pathways were the top-scored target pathways
that were affected by AMA.
Conclusions: Administration of a CAMP causes shift in the balance of immune-inflammatory responses involving
downstream pathways of TLRs in cytotrophoblast function. Further verification of functions of placental
trophoblasts on administration of CAMP with pregnancy outcome is necessary.
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Background
Cationic antimicrobial peptides (CAMPs) are gene-
encoded short chain peptides (10–50 amino acids) hav-
ing an overall positive charge due to the presence of
positively charged amino acids namely lysine, arginine
and histidine. CAMPs contribute to body’s innate im-
mune response and are evolutionarily conserved. These
peptides are broad-spectrum antibiotics as they impart
effective antagonistic action on gram-positive and gram-
negative bacteria, protozoa and fungi [1]. Positively
charged CAMPs interact with negatively charged bacter-
ial cell membrane by electrostatic force of attraction,
which is followed by pore formation in the membrane
and irreversible membrane disruption followed by cell
death [2, 3]. On the other hand, CAMPs normally show
lower affinity towards the mammalian cell membrane
because of differences in its composition, characterized
by the presence of quantitatively lesser aggregation of
negatively charged phospholipids in the outer cell mem-
brane leaflet, and relative abundance of cholesterol as
compared to that of bacterial cell membrane [4].
Additionally, transmembrane potential of bacterial cell
membrane is more polarized to net negativity as com-
pared to the mammalian cell membrane [5]. However,
human placental villous cytotrophoblasts exhibit relative
externalization of negatively charged moieties to the
outer leaflet of the plasma membrane during the time of
syncytialization, thus rendering themselves to be reactive
to the positive charged CAMPs during the window of
implantation [6]. Thus, there is a need for understanding
the action of CAMPs in the process of placentation, as
CAMPs appear to be promising in meeting the need for
new antibiotics.
Ala8,13,18-magainin II amide (AMA) is a synthetic
alpha-helical CAMP and it is modified from natural
Magainin II obtained from African frog, Xenopus leavis.
Magainin II bears significantly high anti-microbial activ-
ity [7]. Furthermore, replacement of three amino acid
residues, namely one serine at position 8 and two glycine
residues at positions 13 and 18, respectively with alanine
renders an enhanced antimicrobial activity in AMA [8].
Additionally, amidation of its terminal amino acid makes
its alpha-helical conformation stabilized and lowers its
susceptibility to exopeptidase action [8]. It shows chem-
ical properties that are very similar to that of human
alpha-helical CAMP, cathelicidin peptide LL-37 [1]. We
have earlier demonstrated using AMA that CAMPs may
exert deleterious action on placental cytotrophoblasts
during blastocyst implantation and early placentation
[9–12], however, the underlying process is not known.
In the present study, we proposed to examine the effect
of application of a synthetic CAMP on the secreted
cytokine profiles of human early placental villous cyto-
trophoblasts in vitro. In order to fulfill the projected
objective of the study, isolated villous cytotrophoblasts
from human placental villi collected during 8–9 weeks
of gestation were maintained in primary culture and ex-
posed to different doses of AMA to simultaneously
examine a panel of forty-eight (48) cytokines in condi-
tioned medium using multiplex immunoassays
technique [13, 14]. Finally, we have examined the steady
state transcript levels of the candidate cyto/chemokines,
the concentrations of which were affected by AMA to
examine the probable level of action of AMA on the
isolated cytotrophoblasts.
Methods
Tissue samples and chemicals
Human placental samples (n = 13) were obtained from
women (age: 22–35 years) undergoing elective surgical
termination of singleton pregnancy between 8 and
9 weeks of gestation (timed from last menstrual period)
without undergoing any prior medication. All women
provided their written informed consents. The Ethics
Committee of the All India Institute of Medical Sciences
approved the research study. Placental samples were
collected in sterile ice-cold phosphate buffered saline
(PBS, pH 7.4) and transported on ice to the laboratory
within 10 min after collection for further processing.
The chemicals were obtained from Sigma Chemical Co.
(St. Louis, MO, USA), if otherwise is not stated.
Isolation of placental villous trophoblast cells
Cytotrophoblasts were isolated from freshly collected
placental villi as described previously [11, 12, 15]. Briefly,
villous tissues (~3 g) were dissected from chorionic
membranes and washed with sterile cold Ca2+/Mg2+ free
PBS (pH 7.4) containing gentamycin (50 μg/ml) and D-
glucose (1 mg/ml). Placental tissues were incubated in
an enzyme mixture [0.25 % (w/v) trypsin, 0.02 % (w/v)
deoxyribonuclease type-I (DNase I), 15 mM HEPES,
5 mM magnesium sulphate, penicillin (100 IU/ml),
streptomycin (100 μg/ml) and amphotericin B (2.5 μg/
ml)] at 37 °C initially for 30 min and then for another
three cycles of 10 min each. Cell suspension was passed
through a pre-equilibrated mesh filter (pore size 60 μm)
to remove cellular debris. The filtrate was subjected to
enrichment on a preformed 10 to 70 % Percoll gradient
at 800× g for 20 min at 20 °C. The mononuclear cells
were immunopurified by depletion of CD45-positive leu-
cocytes using MACS microbeads conjugated with mono-
clonal mouse antibody against CD45 and magnetic
separation columns type LS in combination with a
MidiMACS separator (Miltenyi Biotec, Bergisch
Gladbach, Germany) [11, 12]. The negative fraction con-
taining an enriched villous trophoblast cell population
was collected and immunocharacterised for cytokeratin
7 (CK-7), βhCG, vitronectin receptor (CD51), vimentin
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(Vim) and von Willebrand factor (vWF) as described
below.
Cell culture
The methodological details of cytotrophoblast culture
have been detailed previously [12]. Briefly, isolated mono-
nucleated cytotrophoblast cells were plated at a density of
1 × 105/cm2 on rat-tail collagen I and cultured at 37 °C in
a humidified air atmosphere of 5 % CO2 and in complete
medium [DMEM: F12 (1:1), 10 % (v/v) fetal calf serum,
penicillin (100 IU/ml), streptomycin (100 μg/ml), ampho-
tericin B (2.5 μg/ml)] for 24 h to allow for their
attachment to collagen. Subsequently, the cells were main-
tained in serum-free medium with antibiotics and antimy-
cotics as described above and supplemented with insulin
(5 μg/ml), transferrin (5 μg/ml), selenium (5 ng/ml) and
hydrocortisone (0.5 μg/ml). The same pools of cells were
treated in triplicates without or with AMA at different
doses (1, 10, 100 and 1000 ng/ml) based on our previous
observation that AMA at these concentrations af-
fected synthetic capacity for hCG and hPL without
affecting the viability of the target cells at 24 h in pri-
mary culture [11, 12]. Cells were harvested at 24 h to
obtain cells for immunocytochemical characterisation
of cells and RNA extraction, and conditioned medium
for immunoassays and immunoblot experiments as
described below.
Multiplex assays of cytokines in conditioned media
The details of 48 cytokines, chemokines and growth fac-
tors have been reported elsewhere [13, 14] and are
shown in Additional file 1: Table S1. Cell culture super-
natants were assessed by quantitative cytokine assays
using a Bioplex™ Pro-human cytokine 27-plex panel and
a cytokine 21-plex panel based on xMAP technology
(Bio-Rad Laboratory, Hercules, CA, USA) according to
the pre-optimised protocol as described earlier [13, 14].
Briefly, antibody–conjugated beads were added to indi-
vidual wells of a 96-well filter plate and adhered using
vacuum filtration. After washing, 50 μl of prediluted
standards or conditioned media were added, and the fil-
ter plate was shaken at 300 rpm for 30 min at room
temperature. A prediluted multiplex biotin-conjugated
detection antibody was then added for 30 min. Predi-
luted streptavidin-conjugated phycoerythrin was added
followed by an additional wash and the addition of Bio-
Plex assay buffer. The filter plate was analysed, and
concentrations of each cytokine were determined using
the Bio-Rad Bio-Plex 200 instrument equipped with
BioManager v6.0 software (Bio-Rad). All samples in trip-
licates were assayed in a single run. Standard curves
were generated for each biomarker. Goodness of fit for
standard curves was determined by the standard recov-
ery method and by calculating the concentration of each
standard [16]. The intra-assay variations were less than
10 %. Only those cytokines were selected that could be
detected at ≥0.1 pg/mg Bradford protein in at least 80 %
of cultures.
Immunocytochemistry
After termination of culture at 24 h, cells treated with
and without AMA (1000 ng/ml) were subjected to im-
munofluorescent staining using antibodies against cyto-
keratin 7 (CK-7), βhCG, vitronectin receptor (CD51),
vimentin (Vim) and vWF (see Additional file 2: Table S2
for details of the antibodies used) to check the purity of
the cells using samples (n = 5) in duplicates for both
treatment groups as described earlier [12]. It was as-
sumed that the purity of cells treated with other concen-
trations (1, 10 and 100 ng/ml) of AMA would be
similar. Appropriate fluorochrome-conjugated secondary
antibodies (Molecular Probes, Grand Island, NY, USA)
were used for visualization. Specificity of the antibody
binding was assessed by omitting primary antibodies,
immunoadsorption of primary antibodies with target an-
tigens, replacing primary antibodies with unrelated IgG
from same species and other species, omitting secondary
antibodies, and replacing secondary antibodies with un-
related IgGs from same or other species in parallel
cultures.
Western blotting
Based on the post-hoc analysis of the immunoassays as
described below, two (2) proteins - CCL4 (MIP1B) and
TNF - were chosen to assess their expressions in condi-
tioned medium by employing Western immunoblot
technique as secretion of CCL4 was affected, while TNF
was both very low in medium and was not affected in
isolated cytotrophoblasts following application of AMA
in vitro. The methodological details have been described
elsewhere [12, 13]. After termination, conditioned
medium obtained from cultures with cells treated with-
out (Control, +cells) and with 1000 ng/ml AMA (AMA,
+cells), as well as, unconditioned medium containing
1000 ng/ml AMA (Control, −cells) from different sets
(n = 3) of experiments were subjected to Western immu-
noblot using antibodies against CCL4 and TNF (see
Additional file 2: Table S2 for details of the antibodies)
as described earlier [12, 13]. Briefly, 20 μg Bradford pro-
tein for each sample and the pre-stained molecular
weight markers were separated by SDS-PAGE and sub-
sequent Western immunoblotting techniques were done
using nitrocellulose membranes and chemicals obtained
from Bio-Rad (Hercules, CA, USA). Final visualisation
was achieved using Vectastain ABC immunoperoxidase
kits (Vector Laboratories, Burlingame, CA, USA). Re-
spective primary and secondary antibody controls were
run simultaneously to examine the specificity of the
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antibodies. The molecular weights and semi-quantitative
analysis of the bands were determined using densitomet-
ric equipment (Pharos FX Plus Molecular Imager) and
optimised densitometric analysis software (Quantity
One) from Bio-Rad (Hercules, CA, USA). The measures
of optical densities were performed from the log of in-
verse of transmittance for each target antigen and that
of total stained bands as total secreted protein from
20 μg Bradford protein. The measures of optical dens-
ities for individual immunopositive antigens were calcu-
lated as per cent of total integrated optical densities [17].
Quantitative real time RT-PCR
The relative expression of nine (9) genes of reported cy-
tokines, four (CCL4, CCL5, IL1B, IL6) of which showed
reduced, two (IL1A and TNF) of which did not show
any change and two (IL-2RA and IL16) of which showed
increased secretion following application of AMA to the
cytotrophoblasts were selected as targets from the post-
hoc analysis (as described below) of the Bio-Plex
cytokine data. All samples were assessed using SYBR
Green-based quantitative RT-PCR protocol according to
MIQE guidelines using two most consistently expressed
house-keeping genes, namely glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and ubiquitin C
(UBC) as endogenous controls. The cells treated without
and with 1000 ng/ml AMA (n = 5/each) yielding consist-
ent secretory profile were employed in this experiment
as most significant results were obtained between these
two groups. Thus, the chosen five samples were a subset
of original thirteen samples. The methodological details
were given elsewhere [18]. Briefly, total RNA was ex-
tracted using Trizol (Agilent Technologies Singapore
Pvt. Ltd., Shung Avenue, Singapore), purified with
DNase I and subjected to re-extraction when necessary.
The yield and purity of the extracted RNA were verified
using standard spectrophotometric methods and 1 %
agarose gel electrophoresis. Furthermore, the RIN score
of individual samples was determined using the Agilent
2100 Bioanalyzer, RNA 6000 NanoLabChip kit and
Agilent 2100 Expert Software (Agilent Technologies,
Inc., Santa Clara, CA, USA). The samples yielded suffi-
cient amounts of RNA and an acceptable RIN score
(>8.0) and those RNA samples were used for the experi-
ment. For the real time RT-PCR, the first-strand cDNA
was synthesised from 2 μg of total RNA with an opti-
mised RevertAid™ First Strand cDNA Synthesis Kit
(Fermentas, Germany), and the PCR was performed
using SYBR Green/Fluorescein qPCR Master Mix (Bio-
Rad) and forward and reverse primers for the respective
genes.
The primers for the target genes were designed using
Beacon Designer software (Premier Biosoft, Palo Alto,
CA, USA) as shown in Additional file 3: Table S3 and
obtained from Integrated DNA Technologies (Coralville,
IA, USA). The reaction was performed on a CFX Real
time PCR system from Bio-Rad using an optimised
protocol [19, 20]. Cycle threshold (Ct) values were ob-
tained, and ΔΔCt values for the experimental and con-
trol samples were determined. The relative expression
ratios between groups from cycle threshold (Ct) values
were determined as described elsewhere [19, 20].
Data analysis
The quantitative values of factors in medium and
transcripts in cells from each culture group with dif-
ferent doses of AMA were log transformed and ana-
lysed using the one-way analysis of variance followed
by the Tukey’s test and Student’s t-test, respectively.
Linear regression was done from individual values for
obtaining dose dependent profiles for twelve (12) cy-
tokines that appeared important in post-hoc analysis.
All statistical analyses were done using SPSS v10.0
(SPSS Inc., CA, USA). Significant changes were
derived for each bin showing P < 0.05.
Enrichment analysis
For post hoc enrichment analysis, candidate cyto/chemo-
kines products were matched with known products into
functional ontologies for ‘common’, ‘similar’ and ‘unique’
sets. The probability of a random intersection between a
candidate on the target list and ontology entities was es-
timated in terms of p-values. A lower p-value meant
higher relevance of the entity to the data set due to a
higher rating for the entity. Enrichment analyses were
performed using a cut-off threshold (pFDR(p) = 0.05) for
the secretory cytokines secreted and showing differential
secretion in response to AMA in order to identify the
enriched biological pathways and networks. The Analyze
Networks (AN) algorithm with default settings was
used to retrieve interaction networks that were poten-
tially influenced by AMA. The enrichment analysis
and network constructions were achieved using a
Metacore bioinformatics platform (GeneGO, St.
Joseph, MI, USA) [13, 19, 20].
Results
The cell yield was ~3 × 106 cells/g wet weight of placen-
tal villous tissue with cell viability in trypan blue exclu-
sion method being more than 92 %. As shown in Fig. 1,
these cells were consistently immunopositive for cyto-
keratin 7 (CK-7, 95 ± 2 %) and βhCG (91 ± 4 %) and
negative for vitronectin receptor (CD51; 91 ± 5 %),
vimentin (Vim; 98 ± 1 %) and vWF (99 ± 1 %) with over-
all viability more than 90 % with no significant difference
among treatment groups at the time of experiment.
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Profiles of secreted cyto/chemokines
Sixteen (16) cyto/chemokines (CCL7, CCL11, CCL27,
IFNG, IL2, IL4, IL5, IL7, IL10, IL15, IL17, LTA, NGFB,
PDGFB, SCF and TRAIL) could not be detected in any
sample out of the thirteen (13) samples studied. GMCSF,
IL3, IL12p40, IL12p70 and IL13 could be detected in six
different samples with highly variable dynamic ranges.
These twenty one (21) cytokines, therefore, were not
subjected to further analysis. Table 1 shows the list of
total twenty-seven (27) cytokines which were consist-
ently (>0.1 pg/mg protein in at least 80 % cultures) de-
tected in the conditioned media with isolated
cytotrophoblasts. Except three (3) cytokines (IL9, TNF
and VEGF), all other cytokines were found to be more
than 1 pg/mg protein in the conditioned media.
Differential cyto/chemokine secretion profile following
AMA administration
Analysis of variance of concentrations of the cytokines
consistently detected in conditioned media following dif-
ferent doses of AMA administration identified signifi-
cant (P < 0.05) decrease for seven (7) cytokines (CCL2,
CCL4, CCL5, CXCL1, IL1B, IL6, MIF) following the ap-
plication of 100 and 1000 ng/ml AMA, and additional
three (3) cytokines (CCL3, FGF2, IL8) only following the
application of 1000 ng/ml AMA as compared to that of
the basal control without AMA (Table 1). MCSF (CSF1)
showed significant reduction in all doses of AMA as
compared to the control samples. IL-2RA was detected
in 10–1000 ng/ml AMA treated samples and non-
detectable in samples obtained from no AMA and 1 ng/
ml AMA groups. Of the affected cytokines, a group of
cytokines (CCL2, CCL3, CXCL1, FGF2, IL6, IL8, MCSF,
and MIF) showed a decrease of 2030 % and the other af-
fected cytokines (CCL4, CCL5, IL1B) showed a decrease
of 10–15 % following the administration of AMA. Only
IL16 was higher by about 40 % and IL-2RA was seen to
be induced in 10–1000 ng/ml AMA treated groups as
compared to other two groups (0 and 1 ng/ml AMA).
Based on enrichment analysis, twelve (12) cyto/
chemokines from cytotrophoblasts were selected for
assessing the linear regression between their concentra-
tions and different doses of AMA. As Fig. 2 shows, it re-
vealed significant dose-dependent correlation for CCL3
(P < 0.01), CCL4 (P < 0.05), CCL5 (P < 0.01), IL1B (P <
0.05), IL-2RA (P < 0.05), IL6 (P < 0.01), IL8 (P < 0.01),
IL16 (P < 0.05) and MCSF (P < 0.05). No significant
change was seen in the residual fourteen (14) cytokines
(CLEC11A, CXCL9, CXCL10, CXCL12, GCSF, HGF,
IFNA2, IL1A, IL-1RΑ, IL9, IL18, LIF, TNF, VEGF).
As shown in Fig. 3, Western blot analysis revealed
about 1.5-fold change (P < 0.01) in the level of immuno-
positive CCL4 between conditioned medium obtained
from control cell culture (12.3 ± 2.2) and 1000 ng/ml
AMA containing cell culture (7.1 ± 2.1); both were
higher (P < 0.001) than its level in unconditioned basal
medium. On the other hand, immunopositive TNF level
was extremely low in the conditioned medium obtained
from both control cell culture (2.1 ± 0.6) and
1000 ng/ml AMA culture (1.6 ± 0.5) with statistically
no significant difference, although they were margin-
ally higher (P < 0.05) than that in basal medium with-
out cells (1.0 ± 0.3) (Fig. 3). Thus, the Western blot
analysis revealed vector concordance with their
profiles estimated by using multiplex immunoassays
technique.
Steady state transcript levels of differentially secreted
cytokines
Table 2 shows the comparative profiles of Bio-Plex cyto-
kine data and real time RT-PCR data for nine candidates
(CCL4, CCL5, IL1A, IL1B, IL-2RA, IL6, IL16, MIF and
TNF) based on protein data as seen in Table 1 and the
results of the enrichment analysis (as given in Table 3)
in five samples treated without or with (1000 ng/ml)
AMA from original set of thirteen samples. In addition
to IL1A and TNF which showed no change in the
secretory concentrations as welll, no change was ob-
served in the transcript profiles in any of those cytokines
[CCL4 (MIP1B), CCL5 (RANTES), IL1B and IL6] except
Fig. 1 Immunocytochemical characterization of isolated villous cytotrophoblast cells. Isolated cells were allowed to attach to the collagen
biomatrix and immunostained for cytokeratin 7 (CK-7; a green; 97 % positive), vitronectin receptor (CD51; b green; 95 % negative) and βhCG
(c red; 92 % positive), vimentin (d red; 99 % negative), vWF (e red; 99 % negative). Nuclei are counterstained with DAPI (blue). Bar = 40 μm
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MIF which showed significant decrease in their secreted
concentrations following AMA treatment (Table 2).
However, the steady state transcript levels of IL-2A and
IL16, which showed significantly higher secretion follow-
ing AMA treatment, were also significantly higher in
cells treated with AMA as compared to cells in control
culture (Table 2).
Enrichment analysis
Enrichment analysis based on input list of cyto/chemo-
kines secreted by cytotrophoblasts identified that the in-
tegral modules of inflammatory and immune responses
were potentially involved in the target cells and were af-
fected by the administration of AMA. Figure 4 shows a
snapshot of inflammatory-immunomodulatory pathway
map involving the cyto/chemokines secreted from early
placental villous cyto/chemokines and the ones which
were affected by AMA. Enrichment analysis also re-
vealed that other important cellular modules related to
regulation of cellular proliferation, response to wound
healing and cell chemotaxis were putatively influenced
by the cyto/chemokines secreted by cytotrophoblasts,
and were affected by the administration of AMA. Table 3
shows the summary of the significant outputs of various
enrichment analyses for cyto/chemokines showing differ-
ential secretion between samples with and without
AMA. It is notable that mediators of Toll-like receptors
(TLRs) signaling pathway involving IL1, IL6, MIF, and
TNF was identified in the enrichment analysis of cyto/
chemokines secreted by cytotrophoblasts and those
Table 1 Concentrationa of consistentlyb secreted cytokines in conditioned medium of isolated cytotrophoblasts exposed to AMA for
24 h
Cytokine (Alias) Concentration (ng/ml) of AMA applied
0 1 10 100 1000
CCL2 (MCP1) 96.8 (3.2) 80.8 (10.2) 78.7 (14.6) 73.1** (5.2) 74.5** (5.9)
CCL3 (MIP1Α) 49.0 (2.9) 53.2 (5.2) 53.3 (5.2) 44.4 (3.4) 38.5* (2.1)
CCL4 (MIP1B) 298.0 (22.1) 298.3 (12.9) 350.6 (35.2) 265.2* (12.6) 260.2** (12.4)
CCL5 (RANTES) 362.4 (20.7) 367.9 (30.3) 362.4 (21.3) 332.0* (17.9) 309.7* (11.6)
CLEC11A (SCGFB) 592.1 (58.9) 602.9 (72.0) 609.3 (94.9) 559.7 (68.7) 544.9 (68.4)
CXCL1 (GROΑ) 678.0 (61.2) 688.5 (22.9) 649.2 (33.4) 529.4** (29.3) 527.2** (30.6)
CXCL9 (MIG) 113.2 (10.4) 112.9 (16.0) 114.2 (12.6) 97.1 (15.4) 99.4 (17.9)
CXCL10 (IP-10) 152.7 (12.5) 143.7 (14.2) 119.5 (28.0) 129.9 (29.9) 155.21 (10.74)
CXCL12 (SDF-1) 87.5 (14.1) 89.6 (26.7) 99. 9 (27.5) 83.8 (13.3) 79.6 (23.5)
FGF2 (basic FGF) 4.4 (0.3) 4.9 (0.2) 4.8 (0.2) 4.1 (0.9) 3.2* (0.5)
GCSF (CSF-3) 2307.5 (101.6) 2260.1 (138.4) 2242.3 (160.1) 2127.0 (177.3) 1946.0 (250.6)
HGF (SF) 12501.5 (1648.7) 10638.3 (1955.3) 10935.2 (1194.5) 9930.7 (874.5) 9920.1 (834.8)
IFNA2 4.9 (1.9) 11.1 (5.4) 4.5 (0.9) 4.9 (2.9) 4.7 (1.6)
IL1A 113.4 (14.9) 106.0(15.5) 112.8 (17.0) 128.7 (18.2) 120.6 (13.4)
IL1B 353.0 (23.4) 333.1 (34.2) 322.7 (31.6) 313.5* (26.9) 302.2** (10.6)
IL-1RA 32.9 (2.6) 30.2 (6.1) 27.8 (6.5) 29.5 (1.0) 28.8 (3.0)
IL-2RA (CD25) ND ND 2.3(i) (0.1) 2.2(i) (0.1) 2.9(i) (0.2)
IL6 (IFNΒ2) 752.7 (41.8) 736.2 (40.1) 704.3 (31.3) 611.5** (22.6) 587.8** (26.1)
IL8 (CXCL8) 11779.0 (2146.6) 12706.4 (2868.5) 16701.7 (4785.2) 14902.2 (4615.2) 8302.9* (2435.9)
IL9 (HP40) 0.6 (0.3) 0.3 (0.2) 0.3 (0.2) 0.4 (0.2) 0.3 (0.2)
IL16 (LCF) 11.4(3.9) 11.0 (4.8) 18.7* (2.4) 18.3* (2.6) 18.8* (2.2)
IL18 (IGIF) 28.9 (2.8) 30.2 (2.3) 28.0 (3.0) 25.2 (1.7) 29.2 (1.7)
LIF (DIA) 2.8 (1.2) 2.9 (1.4) 2.9 (1.3) 2.8 (1.2) 3.1 (1.3)
MCSF (CSF1) 174.2 (16.2) 125.9* (23.6) 123.7* (21.3) 121.6* (27.9) 125.6** (7.4)
MIF (MMIF) 2919.2 (178.5) 2790.7 (211.2) 2708.6 (260.7) 2231.1* (261.3) 2154.2** (143.1)
TNF (TNF alpha) 0.6 (0.3) 0.5 (0.2) 0.4 (0.2) 0.4 (0.2) 0.4 (0.3)
VEGF-A (VPF) 0.3 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1)
Values are shown as means with SDs in brackets. apg/mg of Bradford protein. Note that concentrations were estimated in terms of pg per unit mg of secreted
protein (w/w) to avoid any bias in mass per unit volume. b ≥ 0.1 pg/mg of Bradford protein detected in at least 80 % samples. (i)induced. *P < 0.05, **P < 0.01 as
compared to control. ND, values <0.1 pg/mg Bradford protein
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which were affected by the administration of AMA
(Table 3).
Discussion
The natural interaction between embryonic trophoblasts
and maternal uterine cells during blastocyst implantation
and placentation involves several cytokines; the underlying
process in many ways is physiognomonic of an inflamma-
tory state [21, 22]. It is generally considered that cytokines
are produced by immune competent cells. However, it now
appears that various pro- and anti-inflammatory cytokines
are also synthesized and secreted by placental trophoblasts
[23, 24]. The results of the present study, in which we have
used a panel of 48 cytokines, chemokines and growth fac-
tors, indeed substantiates and widens our information in
this regard. The observations from the present study that
human villous cytotrophoblasts isolated from first trimester
placental villi and grown on collagen biomatrix elaborated
27 cytokines reportedly involved in various cellular physi-
ology and pathology [25–28], and that secretion of thirteen
(13) out of 27 cytokines were affected by a model synthetic
cationic antimicrobial peptide (CAMP), i.e., AMA along
with previous reports [21, 23, 24, 29, 30] open up a new
vista for further investigation into the possible impact of
CAMPs on first trimester placental biology [31, 32]. It ap-
pears that the cyto/chemokines and growth factors that
were identified in the conditioned medium of cytotropho-
blasts and the ones which were affected by AMA are gener-
ally known to influence several cellular processes and
pathways ranging from inflammatory responses to immune
Fig. 2 The linearized profiles of putatively important cytokines in the conditioned medium of villous cytotrophoblasts in primary culture following
the administration of different doses (0, 1, 10, 100, 1000 ng/ml) of AMA. Linear regressions were obtained from individual values, taking the
estimated maximum values as 100 % for obtaining dose-dependent profiles. The twelve (12) cytokines were selected based on enrichment
analysis. **P < 0.01. *P < 0.05
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competence, regulation of cellular proliferation to cell
chemotaxis (Table 3, Fig. 5).
Cytokines elaborated by early placental cytotrophoblasts
It is evident from the present investigation that a large
number of cytokines were released by villous cytotro-
phoblasts. Earlier Lash and associates have reported the
presence of some of these cytokines (IL1B, IL8 and
CCL1/MCP1) in multiplex analysis for a dozen of cyto-
kines (IL1B, IL2, IL4, IL5, IL8, IL10, IL12p70, IL13,
IFNG, GMCSF, MCP1 and RANTES) of the conditioned
media of first trimester placental villous and extravillous
cytotrophoblasts [24]. Interestingly, IL12p70 and IL13
were detected in media conditioned with first trimester
villous cytotrophoblasts in the previous study [24],
whereas we found that these two interleukins were de-
tectable only in 45 % samples and were secreted at
highly variable dynamic ranges; hence these two inter-
leukins were considered inconsistent in the present
study. On the other hand, CCL5 (RANTES) which was
consistently detected in conditioned media of villous
cytotrophoblasts in the present study, was not detected
in the previous study [24]. The observed differences
might have resulted from differences in the details of cell
culture protocols used in these two studies. For example,
in the present study the culture medium used was
serum-free, but supplemented with insulin, transferrin,
selenium and hydrocortisone and cells were grown on
collagen I biomatrix, whereas in the previous study 10 %
fetal bovine serum was used and cells were grown on fi-
bronectin coated substratum [24]. Whether these vari-
ables could indeed have resulted in the observed
differences is only conjectural at this point. However, it
is known that differences in the traction forces generated
by the two different extracellular matrix molecules,
namely collagen and fibronectin may differentially influ-
ence gene and protein expressions in cells [33].
AMA affected cytokine secretion by early placental
cytotrophoblasts
The various cyto/chemokines which were seen to be de-
creased in the conditioned media of isolated cytotropho-
blasts by the application of AMA included CCLs-2
(MCP1), 3 (MIP1A), 4 (MIP1B), 5 (RANTES), CXCLs-1
(GROA) and 8 (IL8); these are known to function in
combinatorial manner towards regulating inflammation,
chemotactic movements of pro-inflammatory cells, cell
proliferation and wound healing [34–37].
The growth factors like FGF2 and CSF1 which are
known to support the growth and differentiation of
placental trophoblasts [38–40] were also down-
regulated by AMA. Collectively, our results provide
probable physiological basis of our earlier observation
that application of AMA resulted in the breakdown
of cellular homeostasis in isolated first trimester vil-
lous cytotrophoblasts [9, 10].
We have also observed a relative lowering of secretion
IL1B, IL6 and MIF with no change in the level of
secretory TNF along with increased transcript levels and
secretory concentrations of IL16 and IL-2RΑ by isolated
cytotrophoblasts following AMA treatment in vitro.
There is substantial evidence that the shift in the ratios
of these inflammatory mediators may result in differen-
tial status of oxidative stress, cell proliferation and apop-
tosis, NF-kB recruitment and down-stream signaling,
and regulation of activation of cytoplasmic ‘death do-
main’ in cell specific manner [26, 41–43].
Interestingly, it was observed that AMA did not affect
the steady state transcript levels of the candidate cyto/
chemokines (CCL4, CCL5, IL1A, IL1B and IL6) in the
cytotrophoblasts, the secreted levels of which were re-
duced by in vitro administration of AMA. It may be
speculated that AMA did not change the steady state
transcript profiles of those cyto/chemokines which how-
ever displayed reduced secretion by its action, possibly
on translational, post-translational and secretory
processes. Furthermore, the fact that AMA itself is an
anti-microbial agent and that it down-regulates immune
responsiveness in placenta might be viewed as the result-
ant steady state of intrinsic controlled output of the sys-
tem [44]. This suggestion appears to be probable on














+ Cells - Cells
Fig. 3 Representative Western immunoblots of CCL4 and TNF from
conditioned media without cells (Control, − cells/+AMA), and with
cytotrophoblast cells grown in primary culture on collagen biomatrix
(+ cells) with AMA (1000 ng/ml) and without AMA (Control, +cells).
Media containing 20 μg of Bradford proteins were subjected to
electrophoretic separation followed by immunoblot analysis. The log
transformed measures of optical densities for each target antigen
were calculated as per cent of total integrated optical densities for
total protein loaded as described in the Methods section. The values
for CCL4 in specific experiment were 11.8 (Control, +cells), 6.7 (AMA,
+cells) and 0.7 (Control, −cells/+AMA), and for TNF were 1.6
(Control, +cells), 1.2 (AMA, +cells) and 0.8 (Control, −cells/+AMA) per
cent of integrated optical densities, resepectively
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necessary to understand the underlying molecular mech-
anism of action of CAMPs in this regard.
AMA affected secretion of cytokines by cytotrophoblasts
in differential manner
The results of the present study revealed an interesting
differential effect of AMA on cytokine secretion and the
steady state profiles their respective cytokines by cyto-
trophoblasts in vitro, indicating that the observed effects
of AMA on cytotrophoblasts was not a general one, ra-
ther specific for dose of AMA for individual cytokines.
While the secretion of a few cytokines (CCL2, CCL4,
CCL5, CXCL1, IL1B, IL6, and MIF) was significantly re-
duced by AMA at 100 and 1000 ng/ml, and some
(CCL3, FGF2, and IL8) only at 1000 ng/ml, MCSF
(CSF1) showed significant reduction in all doses of
AMA applied. IL16 and IL-2RA were significantly higher
at 10–1000 ng/ml. Although it signifies that AMA at
1 ng/ml could affect the cellular physiology of cytotro-
phoblasts, only little dose-dependent changes were
observed with clear effect for various cytokines at 100–
1000 ng/ml AMA, and there were also innate differences
in responses of secretion of cytokines with some degree
of specificity in the cytotrophoblasts in primary culture.
The underlying physiological significance and mechan-
ism of these observations of dose-differential effect of
AMA on cytotrophoblasts are only conjectural at
present. However, it brings the issue of physiological
concentration of CAMP in the female reproductive tract
against the administered amount of AMA in the present
study.
The minimum inhibitory concentrations of CAMP
with broad spectrum of antimicrobial activity against
gram-positive and gram-negative bacteria, fungi and
protozoa can be as low as 0.4 μM [45]. The vaginal con-
centration of gene-encoded CAMP, on the other hand,
may rise to as high as 10 μM [46]. It is notable that the
maximum concentration of AMA used in the present
study was 0.4 μM. Thus, apparently the dose of AMA
used was well within the normal level. Nevertheless, we
believe that such generalization needs to be taken with
due caution. For example, AMA is inherently highly
stable synthetic compound because of alanine replace-
ment in 8,13 and 18 positions and its amide residue in
the terminus [8]. Also, AMA administered in the culture
medium by design yields a closed and limited compart-
mental distribution pharmacokinetic system in contrast
to CAMP inherently present in the tissue itself in a
Table 2 Comparative profiles of immunopositive proteins in medium and respective transcripts in cells for selected cytokines in
primary cultures with (1000 ng/ml) and without AMA
Name of cytokine Mean ± SD (n = 5/ea)
Concentration in conditioned mediuma Relative level of transcript in cellsb
Control AMA Control AMA
CCL4 (MIP1B) 298.0 260.2** 2.5 2.6
±22.1 ±12.4 ±0.7 ±0.9
CCL5 (RANTES) 362.4 309.7* 5.2 5.8
±20.7 ±11.6 ±2.7 ±2.1
IL1A 113.4 120.6 2.9 3.6
±14.9 ±13.4 ±2.4 ±2.1
IL1B 353.0 302.2** 2.5 2.9
±23.4 ±10.6 ±1.1 ±1.5
IL-2RA 0.08c 2.9*** 7.3 9.5**
±0.03 ±0.1 ±0.1 ±0.3
IL6 752.7 587.8** 5.8 6.9
±41.8 ±21.1 ±1.2 ±1.8
IL16 11.4 18.8* 7.5 8.8**
±3.9 ±2.2 ±0.1 ±0.2
MIF 2919.2 2154.2 9.8 8.3*
±178.5 ±143.0 ±0.6 ±0.4
TNF 0.6 0.4 3.0 3.1
±0.3 ±0.3 ±0.5 ±0.8
apg per mg Bradford protein from Bio-plex immunoassays and as shown in Table 1. bΔΔCt relative to housekeeping genes (GAPDH and UBC) based on real time
RT-PCR using SYBR green uniplex chemistry. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to control. cvalues <0.1 pg/mg Bradford protein considered
not detectable
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living organism yielding an open and multi-
compartmental pool system. Further experiments are
indeed necessary to retrieve the therapeutic correspond-
ence of synthetic CAMP in the intact system using ap-
propriate model systems [47].
Significance of CAMP action in placental development
The maternal-fetal interface is one of the ‘immune privi-
leged sites’ where active mechanisms of acquired immun-
ity are muted or bypassed as an adaptive function in the
process of evolution of mammalian placenta. We have
earlier reported that first trimester villous cytotropho-
blasts drive relative up-regulation of innate antiviral re-
sponse and down-regulation of adaptive immune response
as the first site of defense [20, 48]. This along with the im-
mune functioning of decidual cells, T-cells, B-cells, macro-
phages and NK cells hold the immune privileged status at
maternal-fetal interface [49]. Substantial evidence suggests
that Toll-like receptor signaling pathway involving IL1,
IL6, and TNF is critical for initiating inflammatory activa-
tion in response to cellular stress [26–28] and during early
placental development [21, 23, 24, 29–32]. Toll-like recep-
tor signaling pathways also involve macrophage migration
inhibitory factor (MIF) which exerts pleotropic action on
several cellular processes including cell survival, apoptosis
and inflammation [50–52]. Primary trophoblast cells of
human placenta suggestively function in a regulated
fashion through the activation of Toll-like receptors
(TLRs) [30, 53].
Figure 5 shows a scheme modeling how Toll-like re-
ceptors signaling may influence the cellular physiology
of placental trophoblasts, and how AMA may affect
Toll-like receptor signaling pathway in first trimester vil-
lous cytotrophoblasts causing changes in ratios of differ-
ent secretory pro-inflammatory cyto/chemokines which
affects the tissue homeostasis by disturbing its functional
synchrony with decidual cells, macrophages and other
immune competent cells involved in placental develop-
ment [54]. Although we have not categorically examined
the mechanism of action of AMA on the cytoptropho-
blasts in the present study, there is substantial evidence
to suggest that some CAMPs can affect signaling path-
ways of TLRs at several levels from receptors, down-
stream signal transduction, activation of NF-kB factors
and genetic levels, collectively resulting in inhibition of
the expression of specific proinflammatory factors which
are generally upregulated by NF-kB [55–57].
The physiological significance of the increased ex-
pression and secretion of IL16 and IL-2RΑ in cytotro-
phoblasts following application of AMA is not clear.
IL16 is a pleotropic cytokine which can influence
chemotaxis, immune and inflammatory responsive-
ness, cellular physiology and transcriptional regulation
in various cells [58–62]; it is known to induce IL-
2RΑ (CD25) expression [63] and functions synergistic-
ally with IL2 to prime T-cell proliferation [64]. It
appears possible that secretory IL16 and IL-2RΑ
(CD25) play significant role in initiating a tolerogenic
Table 3 Summary of top-scored features from reports of enrichment and pathways-networks analysis
Analysis Description of the process (p value) Candidatesd
Gene ontology (GO) cellular
processa
Inflammatory response (5.9E-12) CCL3, CCL4, CCL5, CXCL1, IL1A, IL1B, IL6, IL9, IL18, IL-1RA, IL-2RA, CXCL9,
CXCL10, MIF, TNF
Immune response (6.3E-12) CCL3, CCL4, CCL5, G-CSF, CXCL1, CXCL10, IL1A, IL1B, IL6, IL9, IL18, IL1RA,
IL-2RA, LIF, MIF, TNF, VEGF
Regulation of cell proliferation (6.3E-12) CCL3, CCL4, CCL5, HGF, GCSF, CXCL1, CXCL9, CXCL10, IL1A, IL1B, IL6, IL9,
IL18, IL-1RA, IL-2RA, LIF, MIF, TNF, VEGF
Response to wound healing (6.4E-12) CCL3, CCL4, CCL5, CXCL1, CXCL9, CXCL10, HGF, IL1A, IL1B, IL6, IL9, IL18,
IL-1RA, MIF, TNF, VEGF
Cell chemotaxis (6.5E-12) CLEC11A, CCL4, CCL5, CXCL1, CXCL9, CXCL10, HGF, IL1B, IL6, IL-2RA, VEGF
Enrichment by pathways mapb Cyto/chemokines in inflammation
(3.8E-12)
CCL4, CCL5, CXCL10, IL1A, IL1B, IL6, IL9, TNF
Secreted signals in immune response
(3.9E-12)
CCL4, CCL5, CXCL10, IL1A, IL1B, IL-1RA, IL- 2RA, IL6, IL9, TNF
Most relevant networkc Toll-like receptor signaling pathway
(2.3E-12)
IL1A, IL1B, ΙL6, MIF, TNF
asources: ebi.ac.uk/quickGO/, Portal.genego.com/cgi/, and Amigo.geneontology.org/amigo
btop scored pathways were identified using input list of selected candidates showing differential levels on Metacore GeneGO portal (MetaCore Biomanual 5.0. at
https://portal.genego.com/help/MetaCpre_bio_manual_5) as discussed elsewhere [11, 17, 18]. Source: portal.genego.com/
cThe cyto/chemokines displaying differential secretion following administration of AMA as shown in Table 1 used as the input list for generation of biological
networks using Analyze Networks (AN) algorithm with default settings. This is a variant of the shortest paths algorithm with main parameters of (i) relative
enrichment with the uploaded data from Table 1 and (ii) relative saturation of networks with canonical pathways. These networks are built on the fly and unique
for the uploaded data. In this workflow the networks are prioritized based on the number of fragments of canonical pathways on the network as discussed
elsewhere [17, 18]. Source: Portal.genego.com/
dCyto/chemokines detected in all groups. The negatively affected candidates by AMA are shown in italics and positively affected ones are shown in bold
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profile in the decidua through the recruitment of spe-
cific subpopulation of CD4+ CD25+Foxp3+ regulatory
T-cells [65]. It has been suggested that increased
secretory mature form of IL16 production by tropho-
blasts contributes to the altered balance in the
immune-inflammatory responses often associated with
pregnancy disorder [66]. The immunological and in-
flammatory regulation mechanisms of the placental
environment are altered in recurrent miscarriage
compared with control along with significant up-
regulation of trophoblast mRNA for CD-25 (IL-2RA)
[67]. Thus, it appears plausible based on above-
mentioned studies that the increased secretion of
these two interleukins (IL16, IL-2RA) and decreased
secretion of IL1, IL6 and MIF by cytotrophoblasts fol-
lowing the application of AMA exerts combinatorial
effect intervening the balance of the overall immune-
inflammatory status of the trophoblast bed at steady
state. It is notable in this connection that these cyto-
kines and TLRs are intimately involved in the process
of innate immunity and resistance to tolerogenesis in
allotransplantation [68]. Coolectively, it appears that
CAMPs mediated derangement in the profile of cyto/
chemokines in early placental cytotrophoblasts may
interfere with the normal immunomodulatory and
other functions of placenta [69–71].
Finally, experiments in the present study were per-
formed in vitro using isolated villous cytotrophoblasts
Fig. 4 A snapshot of the top-scored pathway map based on the enrichment distribution sorted by ‘Statistically Significant Maps’ set using
Metacore portal. This pathway map was retrieved from the significant pathways involved in inflammatory responses. Experimental data from all
files is linked to and visualized on the maps as thermometer like figures (red, down-regulated signals; blue, no change) to indicate vector
component of the cytokine expression in the treatment groups. The cluster of cyto/chemokines which were markedly affected by AMA in the
present study are shown in enclosures with broken red lines. B, binding; CM, covalent modification; Cn, competition; CS, complex subunit; IE,
influence on expression; +P, phosphorylation; T, transformation; TR, transcription regulation; Z, catalysis. Green denotes positive effect. Red denotes
negative effect
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from placental samples, and therefore, the interpret-
ation of the results is limited and tentative. Further
verification of functions of placental trophoblasts and
pregnancy outcome upon administration CAMP is ne-
cessary using non-human primate models.
Conclusion
In conclusion, it appears that early placental villous
cytotrophoblasts secrete a host of cytokines, many of
which appear to be affected by the administration of
a synthetic CAMP, Ala8,13,18-magainin II amide
(AMA). Based on previous observations that AMA
has anti-nidatory action and that it has untoward ac-
tion on cellular homeostasis in early placental cyto-
trophoblast, it may be conjectured from the results of
the present study that AMA mediated derangement
in the profile of cyto/chemokines in early placental
cytotrophoblasts may interfere with the normal
immunomodulatory and other functions of placenta.
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Fig. 5 Schematic presentation of a model highlighting the probable mode of action of AMA on placental development. Typically, Toll-like
receptors (TLRs) mediated action in cytotrophoblasts under the influence of adequate stimuli from decidual cells, T-cells, B-cells, macrophages
and NK cells at maternal-fetal interface results in elaboration of a group of cyto/chemokines (CCL2, CCL3, CCL5, CXCL10, IL1, IL6, IL16, IL-2RA, MIF
and TNF) which are associated with inflammatory and tolerogenic activities. Substantial evidence suggests that Toll-like receptor signaling
pathway involving IL1, IL6, and TNF is critical during early placental development. As shown, many of these cytokines via specific receptors and
associated molecules with down-stream engagement of effector moieties (e.g., NF-kB, ERK, MAPK, IP3, DAG and p53) regulate different cellular
processes (e.g., inflammatory responses, cell survival, growth, proliferation, migration and apoptosis) on homotypic and heterotypic cells as shown
by dashed arrows. The helical peptide like AMA with cationic moieties negatively affects the above-mentioned process at multiple levels as shown
by gray arrows. Thus, AMA peptides putatively affect a variety of different cellular outcomes, depending upon the peptide concentrations and the
nature of its interactions with cell membranes and membrane proteins, resulting in inadequacy of cellular homeostasis. The cytokines
upregulated by AMA are shown in blue italics and down-regulated ones by AMA are shown in red italics. For further details, see the Discussion
section and relevant references [12, 19, 21–32, 45–47, 49, 65, 69–71]
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